ScreenerHero

ARGX ARGENX SE

EBR · BE · Healthcare · Biotechnology · argenx.com
809.60EUR-0.71%Mkt Cap: 55.45B $P/E: 35.24

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD
BBIO
BridgeBio Pharma, Inc. - Common Stock
$13.15BUSD
CORT
Corcept Therapeutics Incorporated - Common Stock
$12.56BUSDP/E 264.2

Key Statistics

Company
Market Cap55.45B USD
Enterprise Value49.84B USD
Revenue (TTM)5.78B USD
Gross Profit4.02B USD
Net Income (TTM)1.40B USD
Revenue/Share85.91 EUR
Last Price809.60 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.9K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0010832176
Valuation
P/E (Trailing)35.24
P/E (Forward)24.96
PEG1.13
EV/EBITDA28.43
EV/Revenue8.63
P/S9.60
P/B6.82
EPS (TTM)22.49
EPS (Forward)32.67
52W Range
568.4068% of range925.00
52W High925.00 EUR
52W Low568.40 EUR
Profitability
Gross Margin89.15%
Oper. Margin31.99%
EBITDA Margin30.34%
Profit Margin31.11%
ROE17.64%
ROA14.88%
Growth
Revenue Growth59.30%
Earnings Growth95.20%
Cash Flow & Leverage
Operating CF744.77M USD
CapEx (TTM)121.39M USD
FCF Margin14.33%
FCF Yield1.49%
Net Debt-5.58B USD
Net Debt/EBITDA-3.18
Balance Sheet
Debt/Equity0.01
Current Ratio5.12
Quick Ratio4.52
Book Value/Sh119.57 EUR
Cash/Share82.89 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1045.28 EUR
Upside (mean)+29.1%
Target Range787.69 EUR – 1286.65 EUR
787.69+29.1% to mean1286.65
# Analysts15
Ownership
Shares Out.62.56M
Float62.43M
Insiders0.01%
Institutions48.70%
Technical
SMA 50833.38 (-2.9%)
SMA 200735.69 (+10.0%)
Beta-0.03
S&P 52W Chg14.58%
Avg Vol (30d)72.50K
Avg Vol (10d)64.52K
Technical Indicators
RSI (14)38.9
MACD-3.1314
MACD Signal2.5551
MACD Hist.-5.6865
BB Upper882.12 EUR
BB Middle853.03 EUR
BB Lower823.94 EUR
BB Width6.82%
ATR (14)22.00 EUR
Vol Ratio (20d)1.21x